Physician profile
Stuart Barish
NPI 1003897299
$3,631.53
in general payments reported to CMS, 2019-2025
22 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $339 · 2021: $343 · 2022: $469 · 2023: $296 · 2024: $638 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.70 | 2019-2025 | Rinvoq |
| Madrigal Pharmaceuticals | $313.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $292.82 | 2019-2024 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.47 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Merck Sharp & Dohme LLC | $223.88 | 2019-2022 | |
| Celgene Corporation | $190.43 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $186.41 | 2020-2025 | Injectafer |
| Janssen Biotech, INC. | $172.12 | 2021-2025 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $164.36 | 2019-2025 | |
| Genzyme Corporation | $135.67 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $103.62 | 2019-2024 | |
| Pfizer INC. | $87.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $43.45 | 2022-2025 | Dupixent |
| Amgen INC. | $24.94 | 2025 | Uplizna |
| Novo Nordisk INC | $24.79 | 2025 | Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $24.34 | 2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $23.96 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $21.83 | 2024 | Rebyota |
| Echosens North America, INC. | $20.98 | 2019 | |
| Ucb, INC. | $18.32 | 2024 | Cimzia |
| Qol Medical, LLC | $16.90 | 2021 | |
| Allergan, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Barish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.